X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs SUN PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. SUN PHARMA WOCKHARDT LTD./
SUN PHARMA
 
P/E (TTM) x -24.5 37.6 - View Chart
P/BV x 2.5 4.2 59.6% View Chart
Dividend Yield % 0.0 0.6 0.3%  

Financials

 WOCKHARDT LTD.   SUN PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
SUN PHARMA
Mar-17
WOCKHARDT LTD./
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,012842 120.2%   
Low Rs532572 92.9%   
Sales per share (Unadj.) Rs355.9131.6 270.4%  
Earnings per share (Unadj.) Rs-60.332.7 -184.3%  
Cash flow per share (Unadj.) Rs-46.838.0 -123.1%  
Dividends per share (Unadj.) Rs0.013.50 0.3%  
Dividend yield (eoy) %00.5 0.3%  
Book value per share (Unadj.) Rs257.8152.7 168.8%  
Shares outstanding (eoy) m110.632,399.26 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.25.4 40.4%   
Avg P/E ratio x-12.821.6 -59.2%  
P/CF ratio (eoy) x-16.518.6 -88.6%  
Price / Book Value ratio x3.04.6 64.6%  
Dividend payout %010.7 -0.2%   
Avg Mkt Cap Rs m85,3791,696,877 5.0%   
No. of employees `0006.317.5 35.7%   
Total wages/salary Rs m9,37149,023 19.1%   
Avg. sales/employee Rs Th6,295.018,028.3 34.9%   
Avg. wages/employee Rs Th1,498.32,798.8 53.5%   
Avg. net profit/employee Rs Th-1,066.34,479.5 -23.8%   
INCOME DATA
Net Sales Rs m39,369315,784 12.5%  
Other income Rs m1,2026,232 19.3%   
Total revenues Rs m40,571322,016 12.6%   
Gross profit Rs m18100,893 0.0%  
Depreciation Rs m1,49512,648 11.8%   
Interest Rs m2,5553,998 63.9%   
Profit before tax Rs m-2,83090,479 -3.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m25712,116 2.1%   
Profit after tax Rs m-6,66978,462 -8.5%  
Gross profit margin %031.9 0.1%  
Effective tax rate %-9.113.4 -67.8%   
Net profit margin %-16.924.8 -68.2%  
BALANCE SHEET DATA
Current assets Rs m33,796329,537 10.3%   
Current liabilities Rs m26,917178,870 15.0%   
Net working cap to sales %17.547.7 36.6%  
Current ratio x1.31.8 68.2%  
Inventory Days Days7979 100.5%  
Debtors Days Days8983 107.2%  
Net fixed assets Rs m39,664204,766 19.4%   
Share capital Rs m5532,399 23.1%   
"Free" reserves Rs m27,968363,997 7.7%   
Net worth Rs m28,522366,397 7.8%   
Long term debt Rs m21,73114,361 151.3%   
Total assets Rs m81,620614,102 13.3%  
Interest coverage x-0.123.6 -0.5%   
Debt to equity ratio x0.80 1,943.9%  
Sales to assets ratio x0.50.5 93.8%   
Return on assets %-5.013.4 -37.5%  
Return on equity %-23.421.4 -109.2%  
Return on capital %-7.724.8 -30.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80744,118 22.2%   
Fx outflow Rs m1,78924,484 7.3%   
Net fx Rs m8,01919,634 40.8%   
CASH FLOW
From Operations Rs m68470,822 1.0%  
From Investments Rs m6,302-42,216 -14.9%  
From Financial Activity Rs m-7,695-22,854 33.7%  
Net Cashflow Rs m-6646,107 -10.9%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 5.1 44.8%  
FIIs % 7.7 23.0 33.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   67,757 133,026 50.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   MERCK LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  STERLING BIOTECH  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Aug 21, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS